Anuh Pharma Limited

ANUHPHR6

INE489G01022

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:56 2024-07-16 EDT			5-day change	1st Jan Change
226.2 ^INR	-0.11%		-3.13%	+54.30%

05-31	Anuh Pharma Limited signed an agreement to acquire 10% stake in Huoban Energy 5 Private Limited from Huoban Private Limited for approximately INR 11.6 million.	CI
05-24	Huoban Energy 5 Private Limited announced that it expects to receive INR 20.25 million in funding from Lumax Industries Limited, Anuh Pharma Limited	CI

Huoban Energy 5 Private Limited announced that it expects to receive INR 20.25 million in funding from Lumax Industries Limited, Anuh Pharma Limited

May 23, 2024

Huoban Energy 5 Private Limited announced that it will issue equity shares for the gross proceeds of INR 20,250,000 on May 24, 2024. The transaction will include participation from new investors Lumax Industries Limited will invest INR 8,700,000 and Anuh Pharma Limited will invest INR 11,550,000. Lumax Industries Limited will hold 10% stake and Anuh Pharma Limited will hold 10% stake in Huoban Energy 5 Private Limited.

The transaction has been approved by the board of directors of the company. The transaction is expected to close on August 31, 2024.

Latest news about Anuh Pharma Limited

Anuh Pharma Limited signed an agreement to acquire 10% stake in Huoban Energy 5 Private Limited from Huoban Private Limited for approximately INR 11.6 million.	05-30	CI
Huoban Energy 5 Private Limited announced that it expects to receive INR 20.25 million in funding from Lumax Industries Limited, Anuh Pharma Limited	05-23	CI
Anuh Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	05-17	CI
Anuh Pharma Limited Recommends Dividend for the Financial Year Ended 31 March 2024	05-17	CI
Anuh Pharma Limited Approves Final Dividend for the Financial Year Ended 2022-2023	04-08	CI
Anuh Pharma Limited Appoints Manan Jayesh Vadhan as Company Secretary and Compliance Officer	04-04	CI
Anuh Pharma Limited Announces Completion of Tenure of Jasvantlal Girdharlal Shah as Independent Director	04-01	CI
Anuh Pharma Gets European Regulator's Nod for Anti-Malarial Drug	02-28	MT
Anuh Pharma Limited Announces Resignation of Jinal Dharmil Mehtalia as Company Secretary and Compliance Officer, Effective 14 February, 2024	02-12	CI
Anuh Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-09	CI
Anuh Pharma Limited Announces the Resignation of Hemant Aunt as Company Secretary and Compliance Officer	01-11	CI
Anuh Pharma Limited Announces Appointment of Ms. Jinal Ajay Shah as Company Secretary and Compliance Officer, Effective from 15 January 2024	01-05	CI
Anuh Pharma Limited Approves the Board Appointments	12-13	CI
Anuh Pharma Limited Approves Board Appointments	11-10	CI
Anuh Pharma Limited Approves Board Appointments	23-08-19	CI
Anuh Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-11	CI
Anuh Pharma Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	23-05-19	CI
Anuh Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-19	CI
Anuh Pharma Limited Announces Board Changes	23-05-19	CI
Anuh Pharma Limited Recommends Final Dividend for the Financial Year Ended 31 March 2023	23-05-19	CI
Anuh Pharma Limited Announces Resignation of Lalitkumar P Shah as Non-Executive Director	23-02-10	CI
Anuh Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-10	CI
Anuh Pharma Limited Approves Appointment of Hemant Auti as the Company Secretary & Compliance Officer	23-01-06	CI
Anuh Pharma Limited Announces Resignation of Bharat Gangani as Company Secretary and Compliance Officer	22-10-20	CI
Anuh Pharma Limited Approves Final Dividend for the Financial Year Ended 2021-2022	22-08-06	CI

Chart Anuh Pharma Limited

Duration

Period

More charts

Company Profile

Anuh Pharma Limited is an India-based company, which is engaged in the business of manufacturing and selling of bulk drugs and chemicals. The Company's products include active pharmaceutical ingredients and corticosteroids. Its active pharmaceutical ingredients include macrolides, anti-tb, anti-malarial, anti-bacterial, anti-hypertension, expectorant, quinolones, intermediates and under development. Its macrolides products include erythromycin, erythromycin ethyl succinate, erythromycin stearate, erythromycin estolate, erythromycin propionate and erythromycin phosphate. Its anti-malarial sulfadoxine and pyrimethamine. The Company's anti-hypertension products include losartan potassium, telmisartan and atorvastatin calcium. The Company's corticosteroids include anti-inflammatory, immunosuppressant, anti-pruritic, anti-mitotic, antihistamines and under development. Its anti-inflammatory products include dexamethasone na phosphate, mometasone furoate and clobetasol butyrate.

Sector

Pharmaceuticals

Calendar

2024-08-08 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
ANUH PHARMA LIMITED	+54.30%	136M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+25.40%	45.54B
OTSUKA HOLDINGS CO., LTD.	+34.52%	24.51B
SANDOZ GROUP AG	+27.12%	16.48B
CIPLA LIMITED	+21.19%	14.66B
ZYDUS LIFESCIENCES LIMITED	+71.91%	14.3B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-11.84%	6.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+18.15%	5.87B
STADA ARZNEIMITTEL	-8.87%	5.73B